Eli Lilly and Co. (NYSE:LLY) lost a patent case last Friday. The company had filed a case to stop Actavis (NYSE:ACT) from selling a lung cancer drug Alimta at a lower cost. The German court, however, did not agree with the company and said that Actavis (NYSE:ACT) could sell the generic drug.

The sales of Eli Lilly’s (NYSE:LLY), an Indianapolis based drug company, will get affected by the lower cost that Actavis (NYSE:ACT) will be offering for the drug as the company generated top sales by selling Alimta. Alimta is a drug that is approved to treat a mesothelioma, a rare form of lunch cancer. Eli Lilly (NYSE:LLY), in the year 2014, generated revenues of $2.79 billion from its international sales of the drug.

The patent that Eli Lilly (NYSE:LLY) wanted to get was a combination of two different patents. One was about the chemical composition of the drug and the second was about its administration technique, which included giving the patients specific vitamins to help them recover from the side effects of the drug.

According to the German court’s ruling which was against Eli Lilly (NYSE:LLY) and in favour of Actavis (NYSE:ACT), the latter would not be violating any laws if it decides to introduce a form of dipotassium salt in Germany, while the former’s patent will get expired in December. This ruling contradicts the earlier ruling that was passed last year by a lower court in the country.

Eli Lilly (NYSE:LLY) is now planning on taking the matter to the Supreme Court of Germany. The company will base its appeal on the fact that it has an exclusive right on the drug till June 2021, due to the patents that the company earned on a vitamin regimen that are to be taken with Alimta.

Michael J. Harrington, the senior vice president as well as the general counsel of the company, was disappointed by the court’s decision. He said that the company strongly opposes the court’s decision regarding Alimta’s vitamin regimen patent. He further said that although Alimta’s compound patent owned by the company’s will remain exclusive in Germany throughout 2015, however the Alimta’s vitamin regimen patent would get violated by the introduction of generic pemetrexed products which include alternative form of salt in Europe before June 2021. He said that the company will be taking the matter to the Supreme Court of Germany.

Last year in May, Eli Lilly (NYSE:LLY) faced a similar situation when English High Court ruled against the company by saying that the company’s competitors will not be violating any rules by introducing generic versions of Eli Lilly’s (NYSE:LLY) drug cancer drug in France, Italy, Spain as well as U.K. The company had appealed the court’s decision but the matter is still pending and the hearing is expected to begin today.

The delay in the patents and the growing competition for its different drugs has affected Eli Lilly’s (NYSE:LLY) overall sales. The company is trying to expand its portfolio through accretive deals. In January, the company closed collaboration deals with Merck & Co. Inc (NYSE:MRK) and Bristol-Myers Squibb Co. (NYSE:BMY) for carrying out clinical trials of cancer drugs that were developed by both the companies.

In the last trading session, the stocks of Eli Lilly and Co (NYSE:LLY) were opened at a price of $62.61; the company was able to close the stocks at the same price. The company had a range of $47.53 to $63.38 for its 52 week period. Moreover, the total market capitalization of the company was recorded to be at 70.09 billion with a price earnings ratio of 17.51.

As for Genetic Technologies Limited (ADR)(NASDAQ:GENE), on Monday, during the first hour of trade, the share prices of Genetic Technologies Limited (ADR)(NASDAQ:GENE) jumped up by 19 percent and reached the price of $1.22. The highest price hit the numbers of $1.31 once the company announced its sales figures for the BREVAGen breast cancer test. As compared to the first quarter of the year, the sales figures for the second quarter increased by 37 percent. Consequently, the total sale for the fiscal year 2014 reached 3,935 tests.

On the last trade day, Genetic Technologies Limited (ADR)(NASDAQ:GENE)’s share started at $1.15 and closed at a reduced price of $1.14. As far as the beta and market capitalization of the company are concerned, the figures were reported to be 0.81 and 18.07 million. The company has a $0.97 to $3.00 range over a period of 52 weeks.

Coming to The Medicines Company (NASDAQ:MDCO), on Monday, the company announced that the European Commission, the Committee for Medicinal Products for Human Use and the European Medicines Agency have given Angiox the market authorization. According to the company, the renewal recommendation granted to Angiox by CHMP reaffirms that the risk-benefit analysis lies in the positive direction.

The committee gave its approval only after it had seen the review of safety, efficacy and clinical data. Moreover, the committee also had a look at the risk management graph of Angiox, prior to its authorization. Angiox is an anti-coagulation drug for adult patients. This drug was designed for patients undergoing the procedure of percutaneous coronary intervention. Moreover, this medicine is also used for patients suffering from ST-segment elevation myocardial infarction.

On the last trading day, the company opened its stocks at the price of $28.78 and closed at the price of $28.83. As far as the 52 week high and low of the company is concerned, the figures were reported to be at $41.28 and $23.53 respectively. The earnings per share of the company’s shares were $0.36 whereas its beta was 1.4.